Bristol Myers Squibb (BMS) has reported outcomes from the Phase III CheckMate -816 trial, indicating an overall survival (OS) ...

No. 2 / 2025Zealand Pharma Announces Financial Results for the Full Year 2024A transformational year with significant ...

Nemluvio has received approval from the European Commission to treat moderate to severe atopic dermatitis and prurigo ...

Historically, clinical trials have under-represented women and minorities. Clinical Trial Media's Cara Brant offers ...

Broad-Spectrum Antiviral NV-387 Phase II Clinical Trial Responding to MPox Pandemic in Africa, Readying to Tackle Bird Flu SHELTON, CT / ACCESS ...

HOUSTON - Moleculin Biotech, Inc. (NASDAQ:MBRX), a late-stage pharmaceutical company currently trading near its 52-week low of $0.66, announced it has received the first European regulatory approval ...

These robust figures were mainly driven by a number of promising trials, with the company delivering nine positive high value Phase III studies during the full year 2024. AstraZeneca has seen ...

non-EU member states, as well as non-Council of Europe members states, notably countries in the MENA region (Morocco and Tunisia). The current phase of the European NPM Forum is implemented within the ...

Jan. 27, 2025 (GLOBE NEWSWIRE) -- Allakos Inc. (Company) (Nasdaq: ALLK), today announced topline results from its phase 1 clinical trial of AK006 in chronic spontaneous urticaria (CSU).

The three phases of schizophrenia are the prodromal, active, and residual phases. Symptoms of schizophrenia can depend on the phase. Early symptoms of schizophrenia may be similar to other conditions.